Psychiatrist
Massachusetts General Hospital
Dr. King completed residency in psychiatry at MGH/McLean followed by a fellowship in Consult-Liaison (CL) Psychiatry at MGH and a research fellowship at the MGH Cardiac Psychiatry Research Program. He is particularly interested in optimization of therapy paradigms within psychedelic research as well as the use of psychedelic-assisted therapies in disorders at the mind-body interface. Dr. King is currently the Principal Investigator in a pilot study exploring the feasibility of psilocybin-assisted therapy for irritable bowel syndrome and is the study psychiatrist for a neuroimaging pilot examining the effects of MDMA-assisted therapy for fibromyalgia. He is also co-developing the Harvard Interdisciplinary Program in Psychedelics with colleagues at BWH and BIDMC, a program that provides education and training in psychedelic-assisted therapies for clinicians across the HMS community.
